Armen A. Galoyan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Armen A. Galoyan has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Karina Galoian
Department of Orthopedics, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
4 shared publications E. J. Sarkissian
Orbeli Institute of Physiology NAS RA
3 shared publicationsJ. S. Sarkissian
Orbeli Institute of Physiology NAS RA
3 shared publicationsR. M. Sulkhanyan
Academy of Sciences of Armenia
3 shared publicationsT. K. Kipriyan
Orbeli Institute of Physiology NAS RA
3 shared publicationsY. Kh. Grigorian
Orbeli Institute of Physiology NAS RA
3 shared publications
Latest Publications
- 18 January 2011
- Published by Springer Nature in Neurochemical Research
- Vol. 36 (5) , 812-818
Cytostatic Effect of the Hypothalamic Cytokine PRP-1 is Mediated by mTOR and cMyc Inhibition in High Grade Chondrosarcoma
This study aimed to further elucidate the molecular mechanisms of antiproliferative action of proline rich polypeptide 1 (PRP-1) cytokine, produced by neurosecretory cells of the hypothalamus to be considered as alternative adjuvant therapy for metastatic chondrosarcoma, which does not respond to chemotherapy or radiation and currently without any effective treatment. Rapid cell proliferation assay of human primary cultures from high grade chondrosarcoma patients biopsies and human chondrosarcoma JJ012 cell line indicated 50 and 80% inhibition in PRP-1 treated samples correspondingly. Videomicroscopy detected that despite the treatment there are still dividing cells, meaning that cells are not in the state of dormancy, rather PRP-1 repressed the cell cycle progression, exhibited cytostatic effect. The mammalian target of rapamycin (mTOR) is an intracellular serine/threonine protein kinase that has a crucial role in a nutrient sensitive signaling pathway that regulates cell growth. Experiments with mTOR pathway after PRP-1 (10 μg/ml) treatment indicated statistically significant 30% inhibition of mTOR activity and its 56% inhibition in immunoprecipitates with PRP-1 concentrations effective for cell proliferation inhibition. Treatment with PRP- caused inhibition of mTOR and downstream target cMyc oncogenic transcription factor sufficient to trigger the cytostatic effect in high grade, but not in low grade chondrosarcomas. The fact that lower concentrations than 10 μg/ml peptide with cytostatic effect did not inhibit mTOR, but inhibited cMyc prompted us to assume that PRP-1 binds to two different receptors facilitating the antiproliferative effect.
- 18 January 2011
- Published by Springer Nature in Neurochemical Research
- Vol. 36 (5) , 812-818
Cytostatic Effect of the Hypothalamic Cytokine PRP-1 is Mediated by mTOR and cMyc Inhibition in High Grade Chondrosarcoma
This study aimed to further elucidate the molecular mechanisms of antiproliferative action of proline rich polypeptide 1 (PRP-1) cytokine, produced by neurosecretory cells of the hypothalamus to be considered as alternative adjuvant therapy for metastatic chondrosarcoma, which does not respond to chemotherapy or radiation and currently without any effective treatment. Rapid cell proliferation assay of human primary cultures from high grade chondrosarcoma patients biopsies and human chondrosarcoma JJ012 cell line indicated 50 and 80% inhibition in PRP-1 treated samples correspondingly. Videomicroscopy detected that despite the treatment there are still dividing cells, meaning that cells are not in the state of dormancy, rather PRP-1 repressed the cell cycle progression, exhibited cytostatic effect. The mammalian target of rapamycin (mTOR) is an intracellular serine/threonine protein kinase that has a crucial role in a nutrient sensitive signaling pathway that regulates cell growth. Experiments with mTOR pathway after PRP-1 (10 μg/ml) treatment indicated statistically significant 30% inhibition of mTOR activity and its 56% inhibition in immunoprecipitates with PRP-1 concentrations effective for cell proliferation inhibition. Treatment with PRP- caused inhibition of mTOR and downstream target cMyc oncogenic transcription factor sufficient to trigger the cytostatic effect in high grade, but not in low grade chondrosarcomas. The fact that lower concentrations than 10 μg/ml peptide with cytostatic effect did not inhibit mTOR, but inhibited cMyc prompted us to assume that PRP-1 binds to two different receptors facilitating the antiproliferative effect.
- 7 January 2011
- Published by Springer Nature in Neurochemical Research
- Vol. 36 (5) , 739-745
Proline Rich Polypeptide (PRP-1) Increases the Superoxide-Producing and Ferrihemoglobin Reducing Activities of Cytochrome B558 Isoforms from Human Lymphosarcoma Tissue Cells
- 7 January 2011
- Published by Springer Nature in Neurochemical Research
- Vol. 36 (5) , 739-745
Proline Rich Polypeptide (PRP-1) Increases the Superoxide-Producing and Ferrihemoglobin Reducing Activities of Cytochrome B558 Isoforms from Human Lymphosarcoma Tissue Cells
- 3 November 2010
- Published by Springer Nature in Neurochemical Research
- Vol. 35 (12) , 2001-2017
Concepts of Neuroendocrine Cardiology and Neuroendocrine Immunology, Chemistry and Biology of Signal Molecules
- 3 November 2010
- Published by Springer Nature in Neurochemical Research
- Vol. 35 (12) , 2001-2017
Concepts of Neuroendocrine Cardiology and Neuroendocrine Immunology, Chemistry and Biology of Signal Molecules
- 31 May 2009
- Published by Springer Nature in Neurochemical Research
- Vol. 34 (12) , 2117-2121
Antitumorigenic Effect of Brain Proline Rich Polypeptide-1 in Human Chondrosarcoma
- 31 May 2009
- Published by Springer Nature in Neurochemical Research
- Vol. 34 (12) , 2117-2121
Antitumorigenic Effect of Brain Proline Rich Polypeptide-1 in Human Chondrosarcoma
- 1 September 2008
- Published by SAGE Publications in Cell Transplantation
- Vol. 17 (9) , 1061-1066
Hypothalamic Proline-Rich Polypeptide Enhances Bone Marrow Colony-Forming Cell Proliferation and Stromal Progenitor Cell Differentiation
The AGAPEPAEPAQPGVY proline-rich peptide (PRP-1) was isolated from neurosecretory granules of the bovine neurohypophysis; it is produced by N. supraopticus and N. paraventricularis. It has been shown that PRP-1 has many potentially beneficial biological effects, including immunoregulatory, hematopoietic, antimicrobial, and antineurodegenerative properties. Here we showed that PRP increased colony-forming cell (CFC) proliferation in rat bone marrow (BM) cells in vivo. In PRP-treated rat BM, the CFU number at day 7 and day 14 was considerably increased in comparison with untreated rat BM and no difference was found at day 21 and day 28. The related peptide [arg8]vasopressin did not reveal CFC proliferation. PRP failed to farther increase CFC proliferation in vitro in BM obtained from PRP-treated or untreated rats. After 3–4 days of human BM stromal cell cultivation in the presence of 2–20 μg/ml PRP the appearance of cells expressing CD15, CD10, CD11a, CD11b, CD3, CD4, and CD16 surface antigens did not differ from the untreated cells. PRP increased the appearance of CD14-positive cells upon 3–4-day incubation with both adult and fetal BM stromal cells. Our results suggest a previously undescribed role for the hypothalamic peptide within neurosecretory hypothalamus–bone marrow humoral axis, because PRP enhances BM colony-forming cell proliferation and stromal cell differentiation.
- 1 September 2008
- Published by SAGE Publications in Cell Transplantation
- Vol. 17 (9) , 1061-1066
Hypothalamic Proline-Rich Polypeptide Enhances Bone Marrow Colony-Forming Cell Proliferation and Stromal Progenitor Cell Differentiation
The AGAPEPAEPAQPGVY proline-rich peptide (PRP-1) was isolated from neurosecretory granules of the bovine neurohypophysis; it is produced by N. supraopticus and N. paraventricularis. It has been shown that PRP-1 has many potentially beneficial biological effects, including immunoregulatory, hematopoietic, antimicrobial, and antineurodegenerative properties. Here we showed that PRP increased colony-forming cell (CFC) proliferation in rat bone marrow (BM) cells in vivo. In PRP-treated rat BM, the CFU number at day 7 and day 14 was considerably increased in comparison with untreated rat BM and no difference was found at day 21 and day 28. The related peptide [arg8]vasopressin did not reveal CFC proliferation. PRP failed to farther increase CFC proliferation in vitro in BM obtained from PRP-treated or untreated rats. After 3–4 days of human BM stromal cell cultivation in the presence of 2–20 μg/ml PRP the appearance of cells expressing CD15, CD10, CD11a, CD11b, CD3, CD4, and CD16 surface antigens did not differ from the untreated cells. PRP increased the appearance of CD14-positive cells upon 3–4-day incubation with both adult and fetal BM stromal cells. Our results suggest a previously undescribed role for the hypothalamic peptide within neurosecretory hypothalamus–bone marrow humoral axis, because PRP enhances BM colony-forming cell proliferation and stromal cell differentiation.
- 9 July 2008
- Published by Springer Nature in Neurochemical Research
- Vol. 34 (2) , 379-385
Myc-oncogene Inactivating Effect by Proline Rich Polypeptide (PRP-1) in Chondrosarcoma JJ012 Cells
- 9 July 2008
- Published by Springer Nature in Neurochemical Research
- Vol. 34 (2) , 379-385
Myc-oncogene Inactivating Effect by Proline Rich Polypeptide (PRP-1) in Chondrosarcoma JJ012 Cells
- 1 June 2007
- Published by Pleiades Publishing Ltd in Neurochemical Journal
- Vol. 1 (2) , 160-172
Studies of the protective effect of the hypothalamic peptide PRP-3 on spinal cord neurons at different periods after lateral hemisection
The protective effect of a new neurosecretory cytokine, proline-rich peptide (PRP-3) that is produced by the cells of the hypothalamic paraventricular and supraoptical nuclei was studied after lateral hemisection of the spinal cord. Experiments were performed at different postoperative periods (3, 4, and 5 weeks) under conditions of daily administration of PRP-3 in order to study dynamics of the development of rehabilitation states. Flow of single impulse activity induced by stimulation of the mixed (N. ischiadicus), extensor (N. peroneus communis), and flexor (N. gastrocnemius) nerves, at the level of the transection site and lower than it, on the damaged and symmetrical intact sides of the spinal cord was observed in comparison with the control in the interneurons and motoneurons of the spinal cord after daily administration of PRP-3 for 3–4 weeks. PRP-3 was shown to restore activity of the neurons of the lumbar part of the spinal cord and to cause more pronounced early and late postimpulse manifestations of the activity of spinal cord neurons. Morphological studies demonstrated that PRP-3 exhibited a powerful effect on the migration of motoneurons to the transection site and on intensification of proliferation of glial elements. Moreover, PRP-3 stimulated the migration of motoneurons to more distant regions along with penetration to the white matter at the level of the symmetrical undamaged side of the spinal cord. Glial and neurite penetration into places without symphysis, predominantly in the grey matter of the spinal cord, and the prevention of scar formation in the regions of damage were demonstrated. PRP-3 facilitated active ingrowth of vessels in the damaged regions. This process, in turn, favors regeneration with the restoration of locomotor activity at the rehabilitation stage. PRP-3 prevented scar formation and favored ingrowth of nerve fibers of the white matter in the damaged area and thus prevented degeneration of neuroglial elements. This fact was confirmed by recording activity at the level of the injury and by restoration of locomotor activity on the damaged side. This properties of PRP-3 may allow its use in clinical practice for the prevention of neurodegeneration induced by craniocerebral and spinal trauma.
- 1 June 2007
- Published by Pleiades Publishing Ltd in Neurochemical Journal
- Vol. 1 (2) , 160-172
Studies of the protective effect of the hypothalamic peptide PRP-3 on spinal cord neurons at different periods after lateral hemisection
The protective effect of a new neurosecretory cytokine, proline-rich peptide (PRP-3) that is produced by the cells of the hypothalamic paraventricular and supraoptical nuclei was studied after lateral hemisection of the spinal cord. Experiments were performed at different postoperative periods (3, 4, and 5 weeks) under conditions of daily administration of PRP-3 in order to study dynamics of the development of rehabilitation states. Flow of single impulse activity induced by stimulation of the mixed (N. ischiadicus), extensor (N. peroneus communis), and flexor (N. gastrocnemius) nerves, at the level of the transection site and lower than it, on the damaged and symmetrical intact sides of the spinal cord was observed in comparison with the control in the interneurons and motoneurons of the spinal cord after daily administration of PRP-3 for 3–4 weeks. PRP-3 was shown to restore activity of the neurons of the lumbar part of the spinal cord and to cause more pronounced early and late postimpulse manifestations of the activity of spinal cord neurons. Morphological studies demonstrated that PRP-3 exhibited a powerful effect on the migration of motoneurons to the transection site and on intensification of proliferation of glial elements. Moreover, PRP-3 stimulated the migration of motoneurons to more distant regions along with penetration to the white matter at the level of the symmetrical undamaged side of the spinal cord. Glial and neurite penetration into places without symphysis, predominantly in the grey matter of the spinal cord, and the prevention of scar formation in the regions of damage were demonstrated. PRP-3 facilitated active ingrowth of vessels in the damaged regions. This process, in turn, favors regeneration with the restoration of locomotor activity at the rehabilitation stage. PRP-3 prevented scar formation and favored ingrowth of nerve fibers of the white matter in the damaged area and thus prevented degeneration of neuroglial elements. This fact was confirmed by recording activity at the level of the injury and by restoration of locomotor activity on the damaged side. This properties of PRP-3 may allow its use in clinical practice for the prevention of neurodegeneration induced by craniocerebral and spinal trauma.
- 1 June 2007
- Published by Pleiades Publishing Ltd in Neurochemical Journal
- Vol. 1 (2) , 156-159
The effect of proline-rich polypeptide on reduction of methemoglobin and formation of superoxide by the b558III cytochrome and suprol metalloproteins in vitro
A synthetic analogue of the proline-rich polypeptide (PRP-1) from neurosecretory granules of bovine neurohypophysis (1.5–7 μg/ml) was shown to stimulate reduction of methemoglobin (metHb) and NADPH-dependent formation of superoxide by the b558III cytochrome (cyt) from human erythrocyte membranes in the course of incubation under aerobic conditions at 4°C in vitro. However, increase in the PRP-1 concentration resulted in a decrease in the superoxide-producing activity of the b558III cyt. It was also demonstrated that PRP-1 inhibited superoxide formation in response to the action of the suprol lipoprotein of blood serum.
- 1 June 2007
- Published by Pleiades Publishing Ltd in Neurochemical Journal
- Vol. 1 (2) , 156-159
The effect of proline-rich polypeptide on reduction of methemoglobin and formation of superoxide by the b558III cytochrome and suprol metalloproteins in vitro
A synthetic analogue of the proline-rich polypeptide (PRP-1) from neurosecretory granules of bovine neurohypophysis (1.5–7 μg/ml) was shown to stimulate reduction of methemoglobin (metHb) and NADPH-dependent formation of superoxide by the b558III cytochrome (cyt) from human erythrocyte membranes in the course of incubation under aerobic conditions at 4°C in vitro. However, increase in the PRP-1 concentration resulted in a decrease in the superoxide-producing activity of the b558III cyt. It was also demonstrated that PRP-1 inhibited superoxide formation in response to the action of the suprol lipoprotein of blood serum.
- 28 June 2006
- Published by Springer Nature in Neurochemical Research
- Vol. 31 (6) , 795-803
Treatment and Prophylaxis of Anthrax by New Neurosecretory Cytokines
In 1881, Louis Pasteur described the Bacillus anthracis vaccine, which plays an important role for the treatment and prophylaxis of anthrax. Currently, treatment for anthrax infection involves the use of several different antibiotics, used in combination with vaccines, which possess potential virulence in white mice and guinea pigs. We discovered several new immunomodulators cytokines (polypeptides) produced by the neurosecretory cells of hypothalamus, some of which can be used as drugs for the treatment and prophylaxis of the anthrax. The proline-rich polypeptides, which consist from 10 to 15 amino acids and four proline residues, are of the special interest; one of them (PRP-1), which consist of 15 amino acids and has the following primary structure ALa-GLy-ALa-Pro-GLu-Pro-Ala-GLu-Pro-Ala-GLn-Pro-GLy-Val-Tyr (AGAPEPAEPAQPGVY) possesses antibacterial activity, and a new proline-rich peptide described by Galoyan and called G x -NH2. Both were tested for treatment against the anthrax bacillus or anthrax strain N55 vaccine in guinea pigs and mice in vivo, and in vitro preparations. The results of experiments show that these hypothalamic neurosecretory cytokines have a strong prophylaxis and therapeutic properties towards animals infected by episodic strain of anthrax and anthrax vaccine N55. The conventional concepts concerning the function of hypothalamic neurosecretion and hypothalamic mechanisms of adaptation have to be reconsidered.
- 28 June 2006
- Published by Springer Nature in Neurochemical Research
- Vol. 31 (6) , 795-803
Treatment and Prophylaxis of Anthrax by New Neurosecretory Cytokines
In 1881, Louis Pasteur described the Bacillus anthracis vaccine, which plays an important role for the treatment and prophylaxis of anthrax. Currently, treatment for anthrax infection involves the use of several different antibiotics, used in combination with vaccines, which possess potential virulence in white mice and guinea pigs. We discovered several new immunomodulators cytokines (polypeptides) produced by the neurosecretory cells of hypothalamus, some of which can be used as drugs for the treatment and prophylaxis of the anthrax. The proline-rich polypeptides, which consist from 10 to 15 amino acids and four proline residues, are of the special interest; one of them (PRP-1), which consist of 15 amino acids and has the following primary structure ALa-GLy-ALa-Pro-GLu-Pro-Ala-GLu-Pro-Ala-GLn-Pro-GLy-Val-Tyr (AGAPEPAEPAQPGVY) possesses antibacterial activity, and a new proline-rich peptide described by Galoyan and called G x -NH2. Both were tested for treatment against the anthrax bacillus or anthrax strain N55 vaccine in guinea pigs and mice in vivo, and in vitro preparations. The results of experiments show that these hypothalamic neurosecretory cytokines have a strong prophylaxis and therapeutic properties towards animals infected by episodic strain of anthrax and anthrax vaccine N55. The conventional concepts concerning the function of hypothalamic neurosecretion and hypothalamic mechanisms of adaptation have to be reconsidered.